Alza Expects Doxil-Hycamtin Ovarian Cancer Study Results To Drive Sales
Executive Summary
Alza expects interim results from a Phase III trial comparing its liposomal doxorubicin product Doxil with SmithKline Beecham's Hycamtin (topotecan) in ovarian cancer will accelerate Doxil sales. The results will be presented at the American Society of Clinical Oncology meeting in New Orleans May 20.